Sinco Pharmaceuticals Holdings Limited

SEHK:6833 Stock Report

Market Cap: HK$382.2m

Sinco Pharmaceuticals Holdings Balance Sheet Health

Financial Health criteria checks 5/6

Sinco Pharmaceuticals Holdings has a total shareholder equity of CN¥644.7M and total debt of CN¥327.3M, which brings its debt-to-equity ratio to 50.8%. Its total assets and total liabilities are CN¥1.8B and CN¥1.2B respectively. Sinco Pharmaceuticals Holdings's EBIT is CN¥131.5M making its interest coverage ratio 158.6. It has cash and short-term investments of CN¥282.0M.

Key information

50.8%

Debt to equity ratio

CN¥327.33m

Debt

Interest coverage ratio158.6x
CashCN¥282.01m
EquityCN¥644.70m
Total liabilitiesCN¥1.17b
Total assetsCN¥1.82b

Recent financial health updates

Recent updates

What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You

Oct 04
What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You

Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Aug 16
Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Apr 02
Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Mar 08
Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Nov 07
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Jun 26
A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

May 30
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Oct 26
Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Feb 04
Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Oct 25
I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Jun 10
Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

May 24
Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Apr 20
Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Feb 16
We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 11
How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Dec 07
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Financial Position Analysis

Short Term Liabilities: 6833's short term assets (CN¥1.3B) exceed its short term liabilities (CN¥1.1B).

Long Term Liabilities: 6833's short term assets (CN¥1.3B) exceed its long term liabilities (CN¥29.9M).


Debt to Equity History and Analysis

Debt Level: 6833's net debt to equity ratio (7%) is considered satisfactory.

Reducing Debt: 6833's debt to equity ratio has reduced from 369.6% to 50.8% over the past 5 years.

Debt Coverage: 6833's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: 6833's interest payments on its debt are well covered by EBIT (158.6x coverage).


Balance Sheet


Discover healthy companies